Perceptive Advisors’s Viking Therapeutics VKTX Stock Holding History

Perceptive Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-105,597	Closed	-$2.78M	–	128
2025 Q3	$2.78M	Sell	105,597 -275,103	-72%	-$8.21M	0.08%	77
2025 Q2	$10.1M	Sell	380,700 -128,305	-25%	-$3.38M	0.37%	52
2025 Q1	$12.3M	Sell	509,005 -486,889	-49%	-$15.4M	0.43%	46
2024 Q4	$40.1M	Sell	995,894 -704,093	-41%	-$40.1M	1.1%	28
2024 Q3	$108M	Buy	1,699,987 +978,610	+136%	+$57.4M	2.28%	11
2024 Q2	$38.2M	Sell	721,377 -272,721	-27%	-$17.9M	0.92%	30
2024 Q1	$81.5M	Buy	+994,098	New	+$44.2M	1.43%	22
2023 Q3	–	Sell	-441,147	Closed	-$6.31M	–	105
2023 Q2	$7.15M	Sell	441,147 -430,600	-49%	-$9.02M	0.21%	70
2023 Q1	$14.5M	Buy	+871,747	New	+$9M	0.43%	53
2018 Q4	–	Sell	-64,261	Closed	-$1.12M	–	124
2018 Q3	$1.12M	Buy	+64,261	New	+$765K	0.03%	89

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Perceptive Advisors's VKTX Position: Q4 2025 in Review

Perceptive Advisors sold out of Viking Therapeutics (VKTX) in Q4 2025, closing a stake of 105,597 shares — an estimated $2.78M sold.

Perceptive Advisors first reported a position in VKTX in Q3 2018 and held it in 10 quarters. The position peaked at $108M in Q3 2024. 424 funds tracked by Wall St. Rank hold VKTX as of Q4 2025.

Perceptive Advisors reported no remaining Viking Therapeutics position as of Q4 2025 after selling out during the quarter.
Perceptive Advisors sold 105,597 Viking Therapeutics shares in Q4 2025, an estimated $2.78M.
Perceptive Advisors first reported a position in Viking Therapeutics in Q3 2018 and held it in 10 quarters.
Perceptive Advisors's Viking Therapeutics position peaked at $108M in Q3 2024.
424 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2025.

Based on Perceptive Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.